<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">BIORXIV</journal-id>
<journal-title-group>
<journal-title>bioRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/407429</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="author-type">
<subject>Regular Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>New Results</subject>
</subj-group>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Biochemistry</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Structural instability of I&#x043A;B kinase &#x03B2; promotes autophagic degradation through enhancement of Keap1 binding</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Kanamoto</surname><given-names>Mayu</given-names></name>
<xref ref-type="aff" rid="a1">a</xref>
<xref ref-type="aff" rid="a2">b</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tsuchiya</surname><given-names>Yoshihiro</given-names></name>
<xref ref-type="aff" rid="a1">a</xref>
<xref ref-type="aff" rid="a3">c</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nakao</surname><given-names>Yuki</given-names></name>
<xref ref-type="aff" rid="a1">a</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Suzuki</surname><given-names>Takafumi</given-names></name>
<xref ref-type="aff" rid="a4">d</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Motohashi</surname><given-names>Hozumi</given-names></name>
<xref ref-type="aff" rid="a5">e</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yamamoto</surname><given-names>Masayuki</given-names></name>
<xref ref-type="aff" rid="a4">d</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2566-2452</contrib-id>
<name><surname>Kamata</surname><given-names>Hideaki</given-names></name>
<xref ref-type="aff" rid="a1">a</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<aff id="a1"><label>a</label><institution>Laboratory of Biomedical Chemistry, Department of Molecular Medical Science, Graduate School of Biomedical Science, Hiroshima University</institution>, Hiroshima734-8553, <country>Japan</country></aff>
<aff id="a2"><label>b</label><institution>Department of Dermatology, Mazuda Hospital</institution>, Hiroshima, 735-8585, <country>Japan</country></aff>
<aff id="a3"><label>c</label><institution>Department of Nutrition and Health Promotion, Hiroshima Jogakuin University</institution>, Hiroshima 732-0063</aff>
<aff id="a4"><label>d</label><institution>Department of Medical Biochemistry, Tohoku University Graduate School of Medicine</institution>, Sendai 980-8575, <country>Japan</country></aff>
<aff id="a5"><label>e</label><institution>Department of Gene Expression Regulation, Institute of Development, Aging and Cancer, Tohoku University</institution>, Sendai 980-8575, <country>Japan</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>To whom correspondence should be address: Dr. Hideaki Kamata, Department of Molecular Medical Science, Graduate School of Biomedical Science, Hiroshima University, Kasumi 1-2-3, Minami-ku, Hiroshima, 734-8553, Japan, Telephone: &#x002B;81 (82) 257-5138; FAX: &#x002B;81 (82) 257-5136; E-mail: <email>hkamata@hiroshima-u.ac.jp</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<year>2018</year>
</pub-date>
<elocation-id>407429</elocation-id>
<history>
<date date-type="received">
<day>03</day>
<month>9</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>03</day>
<month>9</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>03</day>
<month>9</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="407429.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<p>IKK&#x03B2;, an essential kinase of NF-&#x043A;B signaling, is composed of an N-terminal kinase domain (KD) and a C-terminal scaffolding domain, containing a ubiquitin-like domain (ULD). The Hsp90 chaperon has special responsibility for folding of protein kinases including IKK&#x03B2;. Here, we found that Hsp90 inhibition induced IKK&#x03B2; degradation, which is partially mediated by Keap1. Geldanamycin (GA), a Hsp90 inhibitor, enhances association of IKK&#x03B2; with Keap1 through the binding site in KD, and translocates IKK&#x03B2; to detergent-insoluble fractions leading its autophagic degradation. An electrophile tBHQ suppressed Keap1-mediated proteasomal Nrf2 degradation but not autophagic IKK&#x03B2; degradation. Substitution mutation of Leu353 to Ala in the ULD destabilizes IKK&#x03B2;, enhances its association with Keap1, translocates it to detergent-insoluble fractions, and causes its autophagic degradation. These results suggest that Keap1 is involved in the degradation of structural destabilized IKK&#x03B2; and negative regulation of NF-&#x043A;B under proteotoxic stress.</p>
</abstract>
<counts>
<page-count count="18"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<label>1</label>
<title>Introduction</title>
<p>NF-&#x043A;B is a critical transcription factor, regulating oxidative stress response, inflammation and carcinogenesis [<xref rid="c1" ref-type="bibr">1</xref>, <xref rid="c2" ref-type="bibr">2</xref>]. In resting cells, NF-&#x043A;B is inactivated by association with inhibitory proteins such as I&#x043A;B<italic>&#x03B1;</italic> that prevent the DNA binding and nuclear transport. A vast array of stimuli including inflammatory cytokines and cellular stress activate NF-&#x043A;B through the I&#x043A;B kinase (IKK) complex, which consists of two catalytic subunits, IKK<italic>&#x03B1;</italic> and IKK&#x03B2;, and a regulatory subunit NEMO/IKK<italic>&#x03B3;</italic> [<xref rid="c3" ref-type="bibr">3</xref>-<xref rid="c6" ref-type="bibr">6</xref>]. While IKK&#x03B2; mediates activation of the canonical NF-&#x043A;B pathway in response to pro-inflammatory stimuli, IKK<italic>&#x03B1;</italic> has an indispensable role in non-canonical NF-&#x043A;B signaling by phosphorylating NF-&#x043A;B2 [<xref rid="c7" ref-type="bibr">7</xref>]. IKK&#x03B2; is composed of kinase domain (KD), ubiquitin-like domain (ULD), scaffold/dimerization domain (SDD), and NEMO-binding domain (NBD). Crystal structure analysis showed that IKK&#x03B2; is activated by trans auto-phosphorylation of Ser171 and Ser181 in the activation loop of KD through higher order oligomerization [<xref rid="c8" ref-type="bibr">8</xref>, <xref rid="c9" ref-type="bibr">9</xref>]. IKK&#x03B2; phosphorylates I&#x043A;B<italic>&#x03B1;</italic> at N-terminal serines, Ser32 and Ser36, which leads to its ubiquitination and proteasomal degradation. These reactions result in nuclear translocation of NF-&#x043A;B and binding of its cognate &#x043A;B sites in the promoters of target genes. The NF-&#x043A;B signaling pathways are associated with a vast number of human diseases, including inflammatory disorders and cancer, which suggests that IKK&#x03B2; can be a potentially important therapeutic target [<xref rid="c10" ref-type="bibr">10</xref>].</p>
<p>Protein folding, maintenance of proteome integrity, and protein homeostasis critically depend on a complex network of molecular chaperones, including conserved heat shock proteins (HSPs) [<xref rid="c11" ref-type="bibr">11</xref>, <xref rid="c12" ref-type="bibr">12</xref>]. Environmental insults perturb cellular proteome homeostasis, triggering the proteotoxic stress response, or heat shock response, that includes the transcriptional up-regulation of genes encoding HSPs. HSPs are classified into several groups based on their molecular weight. For example, Hsp60, Hsp70, and Hsp90 refer to families of HSPs on the order of 60, 70, and 90 kilodaltons in size, respectively. Hsp90, one of the most conserved HSPs, is essential not only in the protective heat shock response but also due to its chaperoning function in folding client proteins to their active conformations [<xref rid="c13" ref-type="bibr">13</xref>]. The Hsp90 chaperon is responsible for folding of protein kinases, and Hsp90 inhibitors such as geldanamycin (GA), stimulate kinase degradation [<xref rid="c14" ref-type="bibr">14</xref>]. It has been reported that Hsp90 is essential for IKK&#x03B2; activity [<xref rid="c15" ref-type="bibr">15</xref>, <xref rid="c16" ref-type="bibr">16</xref>], and Hsp90 inhibition results in IKK&#x03B2; degradation [<xref rid="c15" ref-type="bibr">15</xref>-<xref rid="c17" ref-type="bibr">17</xref>]. Degradation of IKK&#x03B2; is mediated by two major pathways that degrade cellular proteins in cells: the ubiquitin&#x2013;proteasome system (UPS) and autophagy [<xref rid="c17" ref-type="bibr">17</xref>-<xref rid="c19" ref-type="bibr">19</xref>].</p>
<p>Keap1 is a ubiquitin ligase which interacts with a transcription factor Nrf2, a master regulator of the antioxidant response [<xref rid="c20" ref-type="bibr">20</xref>, <xref rid="c21" ref-type="bibr">21</xref>]. Under quiescent conditions, Nrf2 is anchored in the cytoplasm by binding to Keap1, which in turn facilitates its proteolysis by UPS [<xref rid="c22" ref-type="bibr">22</xref>]. Oxidative stress and electrophiles disrupt the Keap1-Nrf2 complex, dissociating Nrf2 from Keap1 and translocating it into the nucleus where it can act as a transcription factor for series of antioxidant genes to defend against oxidative stress. Keap1 also binds to IKK&#x03B2; and causes its degradation through UPS [<xref rid="c18" ref-type="bibr">18</xref>] or autophagy [<xref rid="c23" ref-type="bibr">23</xref>]. There are emerging evidence showing a functional interplay between IKK&#x03B2;/NF-&#x043A;B and Keap1/Nrf2 signaling pathways, which modulates inflammatory and carcinogenic processes.</p>
<p>Inhibition of HSPs or heat shock leads to proteotoxic stress that causes cellular protein damage or conformational changes such as protein misfolding, resulting in protein degradation. IKK&#x03B2; degradation caused by Hsp90 inhibition may reflect an important adaptive cellular response which links proteotoxic stress response to inflammatory stimuli. However, the mechanism of IKK&#x03B2; degradation by Hsp90 inhibition is yet be studied. In this study, we investigated the mechanism by which Hsp90 inhibition causes IKK&#x03B2; degradation and found that structural destabilization of IKK&#x03B2; enhances its binding to Keap1 and promotes its autophagic degradation by different mechanism from that of Nrf2.</p>
</sec>
<sec id="s2">
<label>2</label>
<title>Material and methods</title>
<sec id="s2a">
<label>2.1</label>
<title>Reagents and antibody</title>
<p>Anti-tubulin (H-300) and anti-HA (Y-11) rabbit antibodies were obtained from Santa Cruz Biotechnology. Anti-HA (11867423) rat monoclonal antibody and anti-Keap1 (10503-2-AP) rabbit antibody were purchased from Roche and Proteintech, respectively. Anti-IKK&#x03B2; (2684), anti-phospho-IKK&#x03B2; (2697) and anti-phospho-I&#x043A;B<italic>&#x03B1;</italic> (2859) rabbit antibodies were procured from Cell Signaling. Anti-Flag (M2) mouse antibody was obtained from Sigma. MG132, Chloroquine, GA, 3-methyladenine(3-MA), and cycloheximide (CHX) were procured from Sigma-Aldrich. Tertiary Butylhydroquinone (tBHQ) was purchased from Tokyokasei.</p>
</sec>
<sec id="s2b">
<label>2.2</label>
<title>Cell culture, plasmid transfection, and luciferase assay</title>
<p>Human embryonic kidney (HEK293) and mouse embryonic fibroblast (MEF) cells were cultured in Dulbecco&#x2019;s modified Eagle&#x2019;s medium supplemented with 10&#x0025; fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin G, and 100 &#x03BC;g/ml streptomycin. Keap1 and Nrf2 were amplified from a human cDNA library by polymerase chain reaction (PCR), and cDNAs were cloned in expression vectors encoding HA and Flag sequences. Expression plasmids encoding IKK&#x03B2;, IKK<italic>&#x03B1;</italic>, NEMO/IKK<italic>&#x03B3;</italic> and I&#x043A;B<italic>&#x03B1;</italic> were described previously [<xref rid="c24" ref-type="bibr">24</xref>]. Substitution mutants were generated by PCR. Plasmids were transfected into fibroblasts, which were cultured in Opti-MEM (Invitrogen) using Lipofectamine Plus (Invitrogen), following the manufacturer&#x2019;s instructions. For luciferase assay, cells were transfected with reporters encoding NF-&#x043A;B binding sites (pNF-&#x043A;B luciferase plasmids), or Nrf2 binding sites (pNQO1 luciferase plasmids), together with pRK-TK Renilla-luciferase control plasmids. Luciferase activity was measured using Dual-Luciferase Reporter Assay System (Promega) following the manufacturer&#x2019;s instructions.</p>
</sec>
<sec id="s2c">
<label>2.3</label>
<title>Cell fractionation</title>
<p>Cells were solubilized in buffer A consisting of 20 mM Tris-Cl (pH 7.5), 150 mM NaCl, 10 mM EGTA, 10 mM MgCl2, 60 mM &#x03B2;-glycerophosphate, 1 mM Na3VO4, 1 mM 4-amidino phenyl methyl sulfonyl fluoride, 50 KIU/ml aprotinin, 20 &#x03BC;g/ml pepstatin, 20 &#x03BC;g/ml leupeptin, 2 mM dithiothreitol and 1&#x0025; Triton X-100. After centrifugation at 16,000 x <italic>g</italic> for 20 min at 4&#x00B0;C, the lysates were fractionated into supernatants and pellets. The pellets were then solubilized in buffer B containing 100 mM Tris-Cl, pH 6.8, 2&#x0025; SDS, 5&#x0025; glycerol, and 2.5&#x0025; 2-mercaptoethanol. Cells solubilized in buffer B were used as total cell lysates.</p>
</sec>
<sec id="s2d">
<label>2.4</label>
<title>Immunoprecipitation and immunoblotting</title>
<p>For the immunoprecipitation assay of transfected cells, cell supernatants were incubated with anti-Flag (M2) Sepharose (Sigma), or with an antibody combined with Protein A and Protein G Sepharose (GE Healthcare) at 4&#x00B0;C. For the immunoprecipitation assay of endogenous proteins, cell lysates were incubated with an antibody together with TrueBlot anti-mouse or anti-rabbit IP beads (eBioscience) and subjected to immunoblotting using TrueBlot HRP-conjugated anti-mouse or anti-rabbit IgG antibodies (eBioscience). Proteins separated by gel electrophoresis were transferred to polyvinylidene difluoride membranes (Millipore) by an electroblotting apparatus (Mighty Small Transphor; Amersham) and subjected to immunoblotting using HRP-conjugated anti-mouse or anti-rabbit IgG antibodies (GE Healthcare). Antigen-antibody complexes were detected using SuperSignal West Pico Chemiluminescence System (Pierce).</p>
</sec>
</sec>
<sec id="s3">
<label>3</label>
<title>Results</title>
<sec id="s3a">
<label>3.1.</label>
<title>Inhibition of Hsp90 promotes Keap1-mediated autophagic degradation of IKK&#x03B2; through enhancing Keap1 binding</title>
<p>When cells were treated with GA, the decrease in IKK&#x03B2; levels was slower in <italic>Keap1</italic><sup><italic>-/-</italic></sup> MEF cells than in their wild-type counterparts, suggesting that Keap1 is partially involved in GA-induced IKK&#x03B2; degradation (<xref rid="fig1" ref-type="fig">Fig. 1A</xref>). Inhibitors of autophagy such as chloroquine and 3-MA, but not proteasome inhibitor MG132, delayed GA-induced degradation, indicating that autophagy mainly mediates GA-induced IKK&#x03B2; degradation (<xref rid="fig1" ref-type="fig">Fig. 1B</xref>). Misfolded proteins are known to form detergent-insoluble aggresomes. GA induces translocation of transfected HA-IKK&#x03B2; into detergent-insoluble fractions (<xref rid="fig1" ref-type="fig">Fig. 1C</xref>). IKK&#x03B2; is composed of KD, ULD, SDD, and NBD, and the Keap1 binding motif which includes two essential glutamate residues (E36 and E39) locates in the N-terminal of KD (<xref rid="fig1" ref-type="fig">Fig. 1D</xref>). Immunoprecipitation assay revealed that GA increases binding of IKK&#x03B2; to Keap1 (<xref rid="fig1" ref-type="fig">Fig. 1E</xref>). Glu-to-Ala substitution mutations at E36 and E39 (E36A and E39A) decreased GA-mediated enhanced IKK&#x03B2;-Keap1 association (<xref rid="fig1" ref-type="fig">Fig. 1F</xref>). Besides, these mutations reduced the binding of co-expressed IKK<italic>&#x03B1;</italic> and NEMO/IKK<italic>&#x03B3;</italic> to Keap1. GA-mediated degradation of IKK&#x03B2; mutants (E36A and E39A) were slower than that of wild type IKK&#x03B2; (wt IKK&#x03B2;), suggesting that inhibition of Hsp90 promotes autophagic degradation of IKK&#x03B2; mediated in part by binding to Keap1</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Fig. 1.</label>
<caption><title>Effect of Hsp90 inhibition on IKK&#x03B2;degradation. (A) Role of Keap1 in GA-induced IKK&#x03B2; degradation. WT and <italic>Keap1</italic><sup><italic>-/-</italic></sup> MEFs were incubated with 2 &#x00B5;M GA, and expression levels of IKK&#x03B2; were investigated. (B) Role of autophagy in GA-induced IKK&#x03B2; degradation. HEK293 cells were transfected with HA-IKK&#x03B2; and incubated for 18 h. Then cells were treated with GA in the presence or absence of 20 &#x00B5;M MG132, 20 &#x00B5;M chloroquine, and 4 mM 3MA. (C) Role of GA in IKK&#x03B2; translocation into detergent soluble or insoluble fractions in HA-IKK&#x03B2;-transfected HEK293 cells. (D) Schematic representation of IKK&#x03B2;. Keap1-binding ETGE motif of IKK&#x03B2; is located in the KD. (E, F) Role of E36 and E39 glutamate residues of IKK&#x03B2; ETGE motif in GA-enhanced IKK&#x03B2;-Keap1 association. After 18 h transfection of HEK293 cells with Flag-Keap1 and HA-IKK&#x03B2; (E) or with HA-IKK&#x03B2;, HA-IKK<italic>&#x03B1;</italic> and HA-NEMO/IKK<italic>&#x03B3;</italic> (F), HEK293 cells were treated with GA for 4 h and then proteins were immunoprecipitated with anti-Flag agarose. (G) Involvement of E36 and E39 in GA-induced degradation. After 18 h transfection of HEK293 cells with HA-IKK&#x03B2; mutants, cells were treated with GA. &#x002A;Statistically significance at P &#x003C; 0.05</title></caption>
<graphic xlink:href="407429_fig1.tif"/>
</fig>
</sec>
<sec id="s3b">
<label>3.2</label>
<title>Keap1-mediated IKK&#x03B2; degradation is not inhibited by tBHQ</title>
<p>Cysteine residues in Keap1 are modified by electrophiles, such as tBHQ, or reactive oxygen species, leading to Keap1 dissociation from Nrf2. As a result, Nrf2 is stabilized and it subsequently translocates to the nucleus. To elucidate whether tBHQ stabilizes IKK&#x03B2;, we investigated degradation of IKK&#x03B2; in the presence or absence of tBHQ, in cells treated with GA, and found that tBHQ did not prevent GA-induced IKK&#x03B2; degradation (<xref rid="fig2" ref-type="fig">Fig. 2A</xref>). Co-transfection assay revealed that tBHQ prevented Keap1-induced Nrf2 degradation, but not IKK&#x03B2; degradation (<xref rid="fig2" ref-type="fig">Fig. 2B</xref>). tBHQ promoted Nrf2 activity and prevented Keap1-mediated suppression of Nrf2 (<xref rid="fig2" ref-type="fig">Fig. 2C</xref>). However, it did not inhibit Keap1-mediated suppression of IKK&#x03B2;-induced NF-&#x043A;B activation (<xref rid="fig2" ref-type="fig">Fig. 2D</xref>). Treatment of cells with GA suppressed TNF<italic>&#x03B1;</italic>-induced NF-&#x043A;B activation, and tBHQ did not prevent GA-mediated NF-&#x043A;B suppression (<xref rid="fig2" ref-type="fig">Fig. 2E</xref>). Co-transfection with IKK&#x03B2; significantly activated NF-&#x043A;B, and GA suppressed IKK&#x03B2;-induced NF-&#x043A;B activation (<xref rid="fig2" ref-type="fig">Fig. 2F</xref>). GA-mediated NF-&#x043A;B suppression was not prevented by tBHQ in IKK&#x03B2;-transfected cells. However, GA did not suppress NF-&#x043A;B-activation in cells transfected with RelA, suggesting that GA specifically suppressed IKK&#x03B2; activity (<xref rid="fig2" ref-type="fig">Fig. 2G</xref>). Western blot analysis revealed that GA suppressed TNF-induced IKK&#x03B2; phosphorylation, and tBHQ did not inhibit GA-mediated IKK&#x03B2; suppression (<xref rid="fig2" ref-type="fig">Fig. 2H</xref>). These results indicate that Hsp90 inhibition leads to Keap1-mediated autophagic degradation that is not inhibited by tBHQ.</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Fig. 2.</label>
<caption><title>Inhibitory effect of tBHQ on Keap1-mediated IKK&#x03B2; degradation. (A) Inhibitory effect of tBHQ on GA-mediated IKK&#x03B2; degradation. Cells were treated with GA in the presence or absence of 50 &#x00B5;M tBHQ. (B) Inhibitory effect of tBHQ on Keap1-mediated Nrf2 or/and IKK&#x03B2; degradation. HEK293 cells were transfected with HA-IKK&#x03B2;, HA-Nrf2 and Flag-Keap1, and incubated with or without tBHQ for 18 h. (C) Nrf2 luciferase activity of HEK293 cells transfected with Nrf2-reporter together with Flag-Keap1 and HA-Nrf2 in the presence or absence of tBHQ. (D) NF-&#x03BA;B luciferase activity of HEK293 cells transfected with NF-&#x03BA;B-reporter together with Flag-Keap1 and HA-IKK&#x03B2; in the presence or absence of tBHQ. Both luciferase activities were measured 18 h post-transfection. (E) NF-&#x03BA;B luciferase activity of HEK293 cells transfected with NF-&#x03BA;B reporter, and incubated with or without GA, tBHQ, and 50 ng/ml TNF&#x03B1; (as an inflammation stimulator) for 18 h. (F, G) NF-&#x03BA;B luciferase activity of HEK293 cells transfected with NF-&#x03BA;B reporter together with or without HA-IKK&#x03B2;(F) or Flag-RelA (G), incubated in presence or absence of GA and tBHQ for 18 h. (H) Inhibitory effect of tBHQ on GA-mediated IKK&#x03B2; inactivation and degradation. HEK293 cells were treated with GA for 6 h and then stimulated with TNF&#x03B1; for 20 min. &#x002A; P &#x003C; 0.05, &#x002A;&#x002A; P &#x003C; 0.01</title></caption>
<graphic xlink:href="407429_fig2.tif"/>
</fig>
</sec>
<sec>
<label>3.3</label>
<title>L353A mutation destabilizes IKK&#x03B2; and leads its autophagic degradation</title>
<p>Structural destabilized mutant of IKK&#x03B2; was studied to elucidate whether structural destabilization per se induces autophagic degradation. The ULD interacts with KD and SDD in a highly organized manner that is required for a critical interaction with I&#x043A;B<italic>&#x03B1;</italic> and kinase activity [<xref rid="c8" ref-type="bibr">8</xref>]. We generated several Ala substitution mutants in the ULD and found that Leu-to-Ala substitution mutation at Leu353 abolishes IKK&#x03B2;-induced NF-&#x043A;B activation (<xref rid="fig3" ref-type="fig">Fig. 3A</xref>), which was consistent with previous reports [<xref rid="c8" ref-type="bibr">8</xref>, <xref rid="c25" ref-type="bibr">25</xref>]. Moreover, autophosphorylation was reduced in L353A mutant (<xref rid="fig3" ref-type="fig">Fig. 3B</xref>). Co-transfection of HEK293 cells with HA-IKK&#x03B2; mutants and ubiquitination-resistant HA-I&#x043A;B<italic>&#x03B1;</italic>RR mutant revealed that L353A mutant hardly phosphorylate I&#x043A;B<italic>&#x03B1;</italic> (<xref rid="fig3" ref-type="fig">Fig. 3C</xref>). L353A mutant was localized to the detergent-insoluble fraction (<xref rid="fig3" ref-type="fig">Fig. 3D</xref>). L353A mutant degraded more rapidly than wt IKK&#x03B2;, and the rate of disappearance was faster in the detergent-insoluble fraction than in the detergent-soluble fraction (<xref rid="fig3" ref-type="fig">Fig. 3E</xref>). Degradation of L353A mutant was partially prevented by chloroquine but not by MG132, suggesting that autophagy mainly mediates degradation of structural destabilized L353A mutant (<xref rid="fig3" ref-type="fig">Fig. 3F</xref>).</p>
<fig id="fig3" position="float" fig-type="figure">
<label>Fig. 3.</label>
<caption><title>Effect of L353A mutation in the ULD of IKK&#x03B2; on structural stability or degradation of IKK&#x03B2;. (A) Effect of different HA-IKK&#x03B2; mutations on IKK&#x03B2;-induced NF-&#x03BA;B activation in terms of NF-&#x03BA;B luciferase activity. HEK293 cells were transfected with NF-&#x03BA;B reporter and HA-IKK&#x03B2; mutants. After 18 h, luciferase activities were measured. (B) Effect of HA-IKK&#x03B2; mutants on IKK&#x03B2; autophosphorylation. HEK293 cells were transfected with HA-IKK&#x03B2; mutants and phosphorylation of IKK&#x03B2; was detected by western blot analysis. (C) Effect of HA-IKK&#x03B2; on IKK&#x03B2;-induced I&#x03BA;B&#x03B1; phosphorylation. HEK293 cells were transfected with HA-IKK&#x03B2; mutants together with HA-I&#x03BA;B&#x03B1;RR, and phosphorylation of I&#x03BA;B&#x03B1; was detected by western blot analysis. (D) Role of L353A mutation in HA-IKK&#x03B2; translocation into detergent insoluble or insoluble fractions of HEK293 cells. Cells were transfected with wild type or mutated HA-IKK&#x03B2;(L353A), and expression levels were investigated in total cell lysates, detergent soluble and insoluble fractions. (E) Effect of L353A mutation on IKK&#x03B2; degradation in different fractions. HEK293 cells were transfected with wild type or mutated HA-KK&#x03B2;(L353A) mutant. After incubation with 10 &#x00B5;g/ml CHX, expression levels were investigated in total cell lysates, detergent soluble and insoluble fractions. (F) Autophagy mediates degradation of L353A mutant. HEK293 cells transfected with HA-IKK&#x03B2; or HA- KK&#x03B2;(L353A) mutants were incubated with CHX in the presence or absence of MG132 and chloroquine. &#x002A; P &#x003C; 0.05, &#x002A;&#x002A; P &#x003C; 0.01</title></caption>
<graphic xlink:href="407429_fig3.tif"/>
</fig>
</sec>
<sec id="s3c">
<label>3.4.</label>
<title>L353A mutation increases Keap1 binding</title>
<p>To elucidate whether Keap1 is involved in degradation of L353A mutant, we investigated the interaction of Keap1 to L353A mutant. Immunoprecipitation assay of transfected cells revealed that binding of Keap1 to IKK&#x03B2; is increased in L353A mutant, whereas binding of IKK<italic>&#x03B1;</italic>, IKK&#x03B2; and NEMO/IKK<italic>&#x03B3;</italic> to IKK&#x03B2; were not changed (<xref rid="fig4" ref-type="fig">Fig. 4A</xref>). Additionally, the increased interaction of endogenous Keap1 to L353A mutant was detected in cells (<xref rid="fig4" ref-type="fig">Fig. 4B</xref>). The reduction in the amount of L353A mutant was slower in <italic>Keap1</italic><sup><italic>-/-</italic></sup> than in wt MEFs under CHX treatment, suggesting that Keap1 is involved in L353A degradation (<xref rid="fig4" ref-type="fig">Fig. 4C</xref>). Co-transfection assay revealed that Keap1 degraded L353A mutant more effectively than wt IKK&#x03B2; (<xref rid="fig4" ref-type="fig">Fig. 4D</xref>). We generated expression plasmids encoding double mutants of L353A/E36A and L353A/E39A. L353A/E36A was expressed effectively, whereas L353A/E39A was hardly expressed in cells. Then we compared degradation ratio of L353A/E36A to L353A and found that L353A/E36A is more stable than L353A (<xref rid="fig4" ref-type="fig">Fig. 4E</xref>). These results indicate that structural destabilization of IKK&#x03B2; increases its interaction to Keap1, leading to autophagic degradation.</p>
<fig id="fig4" position="float" fig-type="figure">
<label>Fig. 4.</label>
<caption><p>Effect of L353A mutation on association of IKK&#x03B2; with Keap1 and autophagic degradation. (A) Effect of L353A mutation on IKK&#x03B2;-Keap1 binding. Cells were transfected with wild type or mutated HA-IKK&#x03B2;(L353A) together with Flag-IKK&#x03B1;, Flag-IKK&#x03B2;, Flag-NEMO/IKK&#x03B3;, and Flag-Keap1. After 18 h, cell lysates were immunoprecipitated with an anti-Flag agarose beads, and association of IKK&#x03B2; with IKK&#x03B1;, IKK&#x03B2;, NEMO/IKK&#x03B3;, and Keap1 was investigated. (B) Effect of L353A mutation on association of IKK&#x03B2; with endogenous Keap1. HEK293 cells transfected with HA-IKK&#x03B2; or HA-IKK&#x03B2;(L353A) were immunoprecipitated with an anti-HA antibody. (C) Role of Keap1 in IKK&#x03B2;(L353A) degradation. After transfection of WT and <italic>Keap1</italic><sup><italic>-/-</italic></sup> MEF cells with mutated HA-IKK&#x03B2;(L353A), cells were treated with CHX and degradation of HA- KK&#x03B2;(L353A) was investigated by western blot analysis. (D) Effect of L353A mutation on Keap1-mediated IKK&#x03B2; degradation. HEK293 cells were transfected with HA-IKK&#x03B2; or HA-IKK&#x03B2;(L353A) together with Flag-Keap1, and expression levels were investigated in cell lysates by western blot analysis. (E) Involvement of Keap1-binding motif in degradation of L353A mutant. After 18 h transfection with HA-IKK&#x03B2;(L353A) and double mutant HA-IKK&#x03B2; (L353A/E36A), HEK293 cells were incubated with CHX HA expression was detected by western blot analysis.</p></caption>
<graphic xlink:href="407429_fig4.tif"/>
</fig>
</sec>
</sec>
<sec id="s4">
<label>4</label>
<title>Discussion</title>
<p>The IKK&#x03B2;/NF-&#x043A;B and Keap1/Nrf2 signaling pathways play an essential role in cellular signaling in response to inflammatory stimuli and oxidative stress. It has been reported that activation of NF-&#x043A;B antagonizes Nrf2-mediated transcription by either inhibition of Nrf2-DNA binding [<xref rid="c26" ref-type="bibr">26</xref>] or depriving CREB binding protein (CBP) from Nrf2 and facilitating the interaction of recruited histone deacetylase 3 (HDAC3) at the Nrf2-DNA binding site [<xref rid="c27" ref-type="bibr">27</xref>]. Nrf2-deficient MEFs show greater activation of NF-&#x043A;B in response to lipopolysaccharide (LPS) stimulus [<xref rid="c28" ref-type="bibr">28</xref>], and Nrf2 suppresses NF-&#x043A;B-induced transcriptional upregulation of proinflammatory cytokines, including IL-6 and IL-1&#x03B2; in macrophages [<xref rid="c29" ref-type="bibr">29</xref>]. Indeed, NF-&#x043A;B activation is suppressed in tBHQ-treated cells in which Nrf2 is activated (<xref rid="fig2" ref-type="fig">Fig. 2D, E</xref>, and <xref rid="fig2" ref-type="fig">F</xref>). Thus, cellular responses to inflammatory stimuli and oxidative stress is regulated by crosstalk between the IKK&#x03B2;/NF-&#x043A;B signaling and the Keap1/Nrf2 signaling pathways.</p>
<p>Although Keap1 is involved in structurally destabilized IKK&#x03B2; degradation, the contribution of Keap1 to degradation is partial; thus, other factors would be involved in IKK&#x03B2; degradation as well. Recent study has revealed that Drosophila Kenny, the homolog of mammalian NEMO/IKK<italic>&#x03B3;</italic>, is a selective autophagy receptor that mediates the degradation of the IKK complex [<xref rid="c30" ref-type="bibr">30</xref>]. Drosophila NEMO/IKK<italic>&#x03B3;</italic> has an LC3-interacting region (LIR) or Atg8-interacting motif (AIM) in the N-terminal region which recruits the IKK complex to the autophagosome. This selective autophagic degradation of the IKK complex prevents constitutive activation of the immune deficiency pathway in response to commensal microbiota in Drosophila [<xref rid="c30" ref-type="bibr">30</xref>]. Remarkably, human NEMO/IKK<italic>&#x03B3;</italic> lacks functional LIR/AIM and does not interact with mammalian Atg8-family proteins. Instead, NEMO/IKK&#x03B3; in mammals has been shown to be ubiquitinated, and therefore, could also interact with selective autophagy receptors via ubiquitin tags [<xref rid="c31" ref-type="bibr">31</xref>, <xref rid="c32" ref-type="bibr">32</xref>]. Thus, several mechanisms would be involved in IKK&#x03B2; degradation in cells under proteotoxic stress.</p>
<p>Cells are challenged by various extrinsic and intrinsic insults which provoke proteotoxic stress under conditions of injury, inflammation, and oxidative stress. Proteome homeostasis is essential to maintain cellular fitness and its disturbance is associated with a broad range of human diseases. To protect cells from proteotoxic stress, cells mobilize heat shock proteins including Hsp90 that unfold proteins and proteolysis systems that remove damaged proteins. In this study, it was found that Hsp90 inhibition, which causes proteotoxic stress, enhances interaction of IKK&#x03B2; with Keap1. These findings also suggest that cells respond to proteotoxic stress by regulating IKK&#x03B2;/NF-&#x043A;B and Keap1/Nrf2 signaling pathways. The Keap1/Nrf2 and IKK&#x03B2;/NF-&#x043A;B signaling pathways have interesting features concerning the proteolytic mechanisms such as autophagy and UPS. Keap1 suppresses Nrf2 activation by UPS, whereas it is degraded by autophagy in response to oxidative stress [<xref rid="c33" ref-type="bibr">33</xref>, <xref rid="c34" ref-type="bibr">34</xref>]. IKK&#x03B2; induces NF-&#x043A;B activation through degradation of I&#x043A;B<italic>&#x03B1;</italic> by UPS, whereas it is degraded by autophagy in response to proteotoxic stress. Furthermore, IKK&#x03B2; contributes to the induction of autophagy in an NF-&#x043A;B-independent manner [<xref rid="c35" ref-type="bibr">35</xref>], and Keap1 interacts with p62, a selective autophagy receptor, which binds to Atg8/LC3 protein, resulting in autophagy [<xref rid="c36" ref-type="bibr">36</xref>, <xref rid="c37" ref-type="bibr">37</xref>]. There is a plausibility that oxidative stress and proteotoxic stress induce selective degradation of Keap1 and IKK&#x03B2; by autophagy and provoke specific cellular responses.</p>
</sec>
</body>
<back>
<ack>
<label>5.</label>
<title>Acknowledgments</title>
<p>This work was supported, in whole or in part, by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (#15H01406, # 15H01382, and #23370062). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Ministry of Education, Culture, Sports, Science, and Technology of Japan.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="c1"><label>[1]</label><mixed-citation publication-type="journal"><string-name><given-names>Y.</given-names> <surname>Ben-Neriah</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Karin</surname></string-name>, <article-title>Inflammation meets cancer, with NF-kappaB as the matchmaker</article-title>, <source>Nat Immunol</source>, <volume>12</volume> (<year>2011</year>) <fpage>715</fpage>&#x2013;<lpage>723</lpage>.</mixed-citation></ref>
<ref id="c2"><label>[2]</label><mixed-citation publication-type="journal"><string-name><given-names>M.S.</given-names> <surname>Hayden</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Ghosh</surname></string-name>, <article-title>NF-kappaB, the first quarter-century: remarkable progress and outstanding questions</article-title>, <source>Genes Dev</source>, <volume>26</volume> (<year>2012</year>) <fpage>203</fpage>&#x2013;<lpage>234</lpage>.</mixed-citation></ref>
<ref id="c3"><label>[3]</label><mixed-citation publication-type="journal"><string-name><given-names>J.A.</given-names> <surname>DiDonato</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Hayakawa</surname></string-name>, <string-name><given-names>D.M.</given-names> <surname>Rothwarf</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Zandi</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Karin</surname></string-name>, <article-title>A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB</article-title>, <source>Nature</source>, <volume>388</volume> (<year>1997</year>) <fpage>548</fpage>&#x2013;<lpage>554</lpage>.</mixed-citation></ref>
<ref id="c4"><label>[4]</label><mixed-citation publication-type="journal"><string-name><given-names>F.</given-names> <surname>Mercurio</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Zhu</surname></string-name>, <string-name><given-names>B.W.</given-names> <surname>Murray</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Shevchenko</surname></string-name>, <string-name><given-names>B.L.</given-names> <surname>Bennett</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>D.B.</given-names> <surname>Young</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Barbosa</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Mann</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Manning</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Rao</surname></string-name>, <article-title>IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation</article-title>, <source>Science</source>, <volume>278</volume> (<year>1997</year>) <fpage>860</fpage>&#x2013;<lpage>866</lpage>.</mixed-citation></ref>
<ref id="c5"><label>[5]</label><mixed-citation publication-type="journal"><string-name><given-names>J.D.</given-names> <surname>Woronicz</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Gao</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Cao</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Rothe</surname></string-name>, <string-name><given-names>D.V.</given-names> <surname>Goeddel</surname></string-name>, <article-title>IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK</article-title>, <source>Science</source>, <volume>278</volume> (<year>1997</year>) <fpage>866</fpage>&#x2013;<lpage>869</lpage>.</mixed-citation></ref>
<ref id="c6"><label>[6]</label><mixed-citation publication-type="journal"><string-name><given-names>S.</given-names> <surname>Yamaoka</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Courtois</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Bessia</surname></string-name>, <string-name><given-names>S.T.</given-names> <surname>Whiteside</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Weil</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Agou</surname></string-name>, <string-name><given-names>H.E.</given-names> <surname>Kirk</surname></string-name>, <string-name><given-names>R.J.</given-names> <surname>Kay</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Israel</surname></string-name>, <article-title>Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation</article-title>, <source>Cell</source>, <volume>93</volume> (<year>1998</year>) <fpage>1231</fpage>&#x2013;<lpage>1240</lpage>.</mixed-citation></ref>
<ref id="c7"><label>[7]</label><mixed-citation publication-type="journal"><string-name><given-names>C.</given-names> <surname>Scheidereit</surname></string-name>, <article-title>IkappaB kinase complexes: gateways to NF-kappaB activation and transcription</article-title>, <source>Oncogene</source>, <volume>25</volume> (<year>2006</year>) <fpage>6685</fpage>&#x2013;<lpage>6705</lpage>.</mixed-citation></ref>
<ref id="c8"><label>[8]</label><mixed-citation publication-type="journal"><string-name><given-names>G.</given-names> <surname>Xu</surname></string-name>, <string-name><given-names>Y.C.</given-names> <surname>Lo</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Napolitano</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Wu</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Jiang</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Dreano</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Karin</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Wu</surname></string-name>, <article-title>Crystal structure of inhibitor of kappaB kinase beta</article-title>, <source>Nature</source>, <volume>472</volume> (<year>2011</year>) <fpage>325</fpage>&#x2013;<lpage>330</lpage>.</mixed-citation></ref>
<ref id="c9"><label>[9]</label><mixed-citation publication-type="journal"><string-name><given-names>S.</given-names> <surname>Polley</surname></string-name>, <string-name><given-names>D.B.</given-names> <surname>Huang</surname></string-name>, <string-name><given-names>A.V.</given-names> <surname>Hauenstein</surname></string-name>, <string-name><given-names>A.J.</given-names> <surname>Fusco</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Zhong</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Vu</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Schrofelbauer</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Kim</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Hoffmann</surname></string-name>, <string-name><given-names>I.M.</given-names> <surname>Verma</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Ghosh</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Huxford</surname></string-name>, <article-title>A structural basis for IkappaB kinase 2 activation via oligomerization-dependent trans auto-phosphorylation</article-title>, <source>PLoS biology</source>, <volume>11</volume> (<year>2013</year>) <fpage>e1001581</fpage>.</mixed-citation></ref>
<ref id="c10"><label>[10]</label><mixed-citation publication-type="journal"><string-name><given-names>M.</given-names> <surname>Karin</surname></string-name>, <article-title>Nuclear factor-kappaB in cancer development and progression</article-title>, <source>Nature</source>, <volume>441</volume> (<year>2006</year>) <fpage>431</fpage>&#x2013;<lpage>436</lpage>.</mixed-citation></ref>
<ref id="c11"><label>[11]</label><mixed-citation publication-type="journal"><string-name><given-names>Y.E.</given-names> <surname>Kim</surname></string-name>, <string-name><given-names>M.S.</given-names> <surname>Hipp</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Bracher</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Hayer-Hartl</surname></string-name>, <string-name><given-names>F.U.</given-names> <surname>Hartl</surname></string-name>, <article-title>Molecular chaperone functions in protein folding and proteostasis</article-title>, <source>Annu Rev Biochem</source>, <volume>82</volume> (<year>2013</year>) <fpage>323</fpage>&#x2013;<lpage>355</lpage>.</mixed-citation></ref>
<ref id="c12"><label>[12]</label><mixed-citation publication-type="journal"><string-name><given-names>H.</given-names> <surname>Saibil</surname></string-name>, <article-title>Chaperone machines for protein folding, unfolding and disaggregation</article-title>, <source>Nat Rev Mol Cell Biol</source>, <volume>14</volume> (<year>2013</year>) <fpage>630</fpage>&#x2013;<lpage>642</lpage>.</mixed-citation></ref>
<ref id="c13"><label>[13]</label><mixed-citation publication-type="journal"><string-name><given-names>M.</given-names> <surname>Taipale</surname></string-name>, <string-name><given-names>D.F.</given-names> <surname>Jarosz</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Lindquist</surname></string-name>, <article-title>HSP90 at the hub of protein homeostasis: emerging mechanistic insights</article-title>, <source>Nat Rev Mol Cell Biol</source>, <volume>11</volume> (<year>2010</year>) <fpage>515</fpage>&#x2013;<lpage>528</lpage>.</mixed-citation></ref>
<ref id="c14"><label>[14]</label><mixed-citation publication-type="journal"><string-name><given-names>A.J.</given-names> <surname>Caplan</surname></string-name>, <string-name><given-names>A.K.</given-names> <surname>Mandal</surname></string-name>, <string-name><given-names>M.A.</given-names> <surname>Theodoraki</surname></string-name>, <article-title>Molecular chaperones and protein kinase quality control</article-title>, <source>Trends Cell Biol</source>, <volume>17</volume> (<year>2007</year>) <fpage>87</fpage>&#x2013;<lpage>92</lpage>.</mixed-citation></ref>
<ref id="c15"><label>[15]</label><mixed-citation publication-type="journal"><string-name><given-names>G.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Cao</surname></string-name>, <string-name><given-names>D.V.</given-names> <surname>Goeddel</surname></string-name>, <article-title>TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90</article-title>, <source>Mol Cell</source>, <volume>9</volume> (<year>2002</year>) <fpage>401</fpage>&#x2013;<lpage>410</lpage>.</mixed-citation></ref>
<ref id="c16"><label>[16]</label><mixed-citation publication-type="journal"><string-name><given-names>M.</given-names> <surname>Broemer</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Krappmann</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Scheidereit</surname></string-name>, <article-title>Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation</article-title>, <source>Oncogene</source>, <volume>23</volume> (<year>2004</year>) <fpage>5378</fpage>&#x2013;<lpage>5386</lpage>.</mixed-citation></ref>
<ref id="c17"><label>[17]</label><mixed-citation publication-type="journal"><string-name><given-names>G.</given-names> <surname>Qing</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Yan</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Xiao</surname></string-name>, <article-title>Hsp90 inhibition results in autophagy-mediated proteasome-independent degradation of IkappaB kinase (IKK)</article-title>, <source>Cell Res</source>, <volume>16</volume> (<year>2006</year>) <fpage>895</fpage>&#x2013;<lpage>901</lpage>.</mixed-citation></ref>
<ref id="c18"><label>[18]</label><mixed-citation publication-type="journal"><string-name><given-names>D.F.</given-names> <surname>Lee</surname></string-name>, <string-name><given-names>H.P.</given-names> <surname>Kuo</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>C.K.</given-names> <surname>Chou</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Xia</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Du</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Shen</surname></string-name>, <string-name><given-names>C.T.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Huo</surname></string-name>, <string-name><given-names>M.C.</given-names> <surname>Hsu</surname></string-name>, <string-name><given-names>C.W.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Ding</surname></string-name>, <string-name><given-names>T.L.</given-names> <surname>Liao</surname></string-name>, <string-name><given-names>C.C.</given-names> <surname>Lai</surname></string-name>, <string-name><given-names>A.C.</given-names> <surname>Lin</surname></string-name>, <string-name><given-names>Y.H.</given-names> <surname>Chang</surname></string-name>, <string-name><given-names>S.F.</given-names> <surname>Tsai</surname></string-name>, <string-name><given-names>L.Y.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>M.C.</given-names> <surname>Hung</surname></string-name>, <article-title>KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta</article-title>, <source>Mol Cell</source>, <volume>36</volume> (<year>2009</year>) <fpage>131</fpage>&#x2013;<lpage>140</lpage>.</mixed-citation></ref>
<ref id="c19"><label>[19]</label><mixed-citation publication-type="journal"><string-name><given-names>M.</given-names> <surname>Niida</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Tanaka</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Kamitani</surname></string-name>, <article-title>Downregulation of active IKK beta by Ro52-mediated autophagy</article-title>, <source>Mol Immunol</source>, <volume>47</volume> (<year>2010</year>) <fpage>2378</fpage>&#x2013;<lpage>2387</lpage>.</mixed-citation></ref>
<ref id="c20"><label>[20]</label><mixed-citation publication-type="journal"><string-name><given-names>Y.</given-names> <surname>Hirotsu</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Katsuoka</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Funayama</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Nagashima</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Nishida</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Nakayama</surname></string-name>, <string-name><given-names>J.D.</given-names> <surname>Engel</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Yamamoto</surname></string-name>, <article-title>Nrf2-MafG heterodimers contribute globally to antioxidant and metabolic networks</article-title>, <source>Nucleic Acids Res</source>, <volume>40</volume> (<year>2012</year>) <fpage>10228</fpage>&#x2013;<lpage>10239</lpage>.</mixed-citation></ref>
<ref id="c21"><label>[21]</label><mixed-citation publication-type="journal"><string-name><given-names>K.</given-names> <surname>Itoh</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Wakabayashi</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Katoh</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Ishii</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Igarashi</surname></string-name>, <string-name><given-names>J.D.</given-names> <surname>Engel</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Yamamoto</surname></string-name>, <article-title>Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain</article-title>, <source>Genes Dev</source>, <volume>13</volume> (<year>1999</year>) <fpage>76</fpage>&#x2013;<lpage>86</lpage>.</mixed-citation></ref>
<ref id="c22"><label>[22]</label><mixed-citation publication-type="journal"><string-name><given-names>T.</given-names> <surname>Suzuki</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Motohashi</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Yamamoto</surname></string-name>, <article-title>Toward clinical application of the Keap1-Nrf2 pathway</article-title>, <source>Trends Pharmacol Sci</source>, <volume>34</volume> (<year>2013</year>) <fpage>340</fpage>&#x2013;<lpage>346</lpage>.</mixed-citation></ref>
<ref id="c23"><label>[23]</label><mixed-citation publication-type="journal"><string-name><given-names>J.E.</given-names> <surname>Kim</surname></string-name>, <string-name><given-names>D.J.</given-names> <surname>You</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Lee</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Ahn</surname></string-name>, <string-name><given-names>J.Y.</given-names> <surname>Seong</surname></string-name>, <string-name><given-names>J.I.</given-names> <surname>Hwang</surname></string-name>, <article-title>Suppression of NF-kappaB signaling by KEAP1 regulation of IKKbeta activity through autophagic degradation and inhibition of phosphorylation</article-title>, <source>Cell Signal</source>, <volume>22</volume> (<year>2010</year>) <fpage>1645</fpage>&#x2013;<lpage>1654</lpage>.</mixed-citation></ref>
<ref id="c24"><label>[24]</label><mixed-citation publication-type="journal"><string-name><given-names>Y.</given-names> <surname>Tsuchiya</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Asano</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Nakayama</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Kato</surname>, <suffix>Jr.</suffix></string-name>, <string-name><given-names>M.</given-names> <surname>Karin</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Kamata</surname></string-name>, <article-title>Nuclear IKKbeta is an adaptor protein for IkappaBalpha ubiquitination and degradation in UV-induced NF-kappaB activation</article-title>, <source>Mol Cell</source>, <volume>39</volume> (<year>2010</year>) <fpage>570</fpage>&#x2013;<lpage>582</lpage>.</mixed-citation></ref>
<ref id="c25"><label>[25]</label><mixed-citation publication-type="journal"><string-name><given-names>M.J.</given-names> <surname>May</surname></string-name>, <string-name><given-names>S.E.</given-names> <surname>Larsen</surname></string-name>, <string-name><given-names>J.H.</given-names> <surname>Shim</surname></string-name>, <string-name><given-names>L.A.</given-names> <surname>Madge</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Ghosh</surname></string-name>, <article-title>A novel ubiquitin-like domain in IkappaB kinase beta is required for functional activity of the kinase</article-title>, <source>J Biol Chem</source>, <volume>279</volume> (<year>2004</year>) <fpage>45528</fpage>&#x2013;<lpage>45539</lpage>.</mixed-citation></ref>
<ref id="c26"><label>[26]</label><mixed-citation publication-type="journal"><string-name><given-names>M.</given-names> <surname>Yu</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Tang</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Yuan</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Zhan</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Xu</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Ge</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Yang</surname></string-name>, <article-title>Nuclear factor p65 interacts with Keap1 to repress the Nrf2-ARE pathway</article-title>, <source>Cell Signal</source>, <volume>23</volume> (<year>2011</year>) <fpage>883</fpage>&#x2013;<lpage>892</lpage>.</mixed-citation></ref>
<ref id="c27"><label>[27]</label><mixed-citation publication-type="journal"><string-name><given-names>G.H.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Qu</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Shen</surname></string-name>, <article-title>NF-kappaB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK</article-title>, <source>Biochim Biophys Acta</source>, <volume>1783</volume> (<year>2008</year>) <fpage>713</fpage>&#x2013;<lpage>727</lpage>.</mixed-citation></ref>
<ref id="c28"><label>[28]</label><mixed-citation publication-type="journal"><string-name><given-names>R.K.</given-names> <surname>Thimmulappa</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Lee</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Rangasamy</surname></string-name>, <string-name><given-names>S.P.</given-names> <surname>Reddy</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Yamamoto</surname></string-name>, <string-name><given-names>T.W.</given-names> <surname>Kensler</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Biswal</surname></string-name>, <article-title>Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis</article-title>, <source>J Clin Invest</source>, <volume>116</volume> (<year>2006</year>) <fpage>984</fpage>&#x2013;<lpage>995</lpage>.</mixed-citation></ref>
<ref id="c29"><label>[29]</label><mixed-citation publication-type="journal"><string-name><given-names>E.H.</given-names> <surname>Kobayashi</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Suzuki</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Funayama</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Nagashima</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Hayashi</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Sekine</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Tanaka</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Moriguchi</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Motohashi</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Nakayama</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Yamamoto</surname></string-name>, <article-title>Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription</article-title>, <source>Nat Commun</source>, <volume>7</volume> (<year>2016</year>) <fpage>11624</fpage>.</mixed-citation></ref>
<ref id="c30"><label>[30]</label><mixed-citation publication-type="journal"><string-name><given-names>R.</given-names> <surname>Tusco</surname></string-name>, <string-name><given-names>A.C.</given-names> <surname>Jacomin</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Jain</surname></string-name>, <string-name><given-names>B.S.</given-names> <surname>Penman</surname></string-name>, <string-name><given-names>K.B.</given-names> <surname>Larsen</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Johansen</surname></string-name>, <string-name><given-names>I.P.</given-names> <surname>Nezis</surname></string-name>, <article-title>Kenny mediates selective autophagic degradation of the IKK complex to control innate immune responses</article-title>, <source>Nat Commun</source>, <volume>8</volume> (<year>2017</year>) <fpage>1264</fpage>.</mixed-citation></ref>
<ref id="c31"><label>[31]</label><mixed-citation publication-type="journal"><string-name><given-names>T.</given-names> <surname>Zotti</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Scudiero</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Settembre</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Ferravante</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Mazzone</surname></string-name>, <string-name><given-names>L.</given-names> <surname>D&#x2019;Andrea</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Reale</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Vito</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Stilo</surname></string-name>, <article-title>TRAF6-mediated ubiquitination of NEMO requires p62/sequestosome-1</article-title>, <source>Mol Immunol</source>, <volume>58</volume> (<year>2014</year>) <fpage>27</fpage>&#x2013;<lpage>31</lpage>.</mixed-citation></ref>
<ref id="c32"><label>[32]</label><mixed-citation publication-type="journal"><string-name><given-names>P.M.</given-names> <surname>Fliss</surname></string-name>, <string-name><given-names>T.P.</given-names> <surname>Jowers</surname></string-name>, <string-name><given-names>M.M.</given-names> <surname>Brinkmann</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Holstermann</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Mack</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Dickinson</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Hohenberg</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Ghazal</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Brune</surname></string-name>, <article-title>Viral mediated redirection of NEMO/IKKgamma to autophagosomes curtails the inflammatory cascade</article-title>, <source>PLoS Pathog</source>, <volume>8</volume> (<year>2012</year>) <fpage>e1002517</fpage>.</mixed-citation></ref>
<ref id="c33"><label>[33]</label><mixed-citation publication-type="journal"><string-name><given-names>K.</given-names> <surname>Taguchi</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Fujikawa</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Komatsu</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Ishii</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Unno</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Akaike</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Motohashi</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Yamamoto</surname></string-name>, <article-title>Keap1 degradation by autophagy for the maintenance of redox homeostasis</article-title>, <source>Proc Natl Acad Sci U S A</source>, <volume>109</volume> (<year>2012</year>) <fpage>13561</fpage>&#x2013;<lpage>13566</lpage>.</mixed-citation></ref>
<ref id="c34"><label>[34]</label><mixed-citation publication-type="journal"><string-name><given-names>S.H.</given-names> <surname>Bae</surname></string-name>, <string-name><given-names>S.H.</given-names> <surname>Sung</surname></string-name>, <string-name><given-names>S.Y.</given-names> <surname>Oh</surname></string-name>, <string-name><given-names>J.M.</given-names> <surname>Lim</surname></string-name>, <string-name><given-names>S.K.</given-names> <surname>Lee</surname></string-name>, <string-name><given-names>Y.N.</given-names> <surname>Park</surname></string-name>, <string-name><given-names>H.E.</given-names> <surname>Lee</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Kang</surname></string-name>, <string-name><given-names>S.G.</given-names> <surname>Rhee</surname></string-name>, <article-title>Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation of Keap1 and prevent oxidative liver damage</article-title>, <source>Cell Metab</source>, <volume>17</volume> (<year>2013</year>) <fpage>73</fpage>&#x2013;<lpage>84</lpage>.</mixed-citation></ref>
<ref id="c35"><label>[35]</label><mixed-citation publication-type="journal"><string-name><given-names>A.</given-names> <surname>Criollo</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Senovilla</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Authier</surname></string-name>, <string-name><given-names>M.C.</given-names> <surname>Maiuri</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Morselli</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Vitale</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Kepp</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Tasdemir</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Galluzzi</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Shen</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Tailler</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Delahaye</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Tesniere</surname></string-name>, <string-name><given-names>D.</given-names> <surname>De Stefano</surname></string-name>, <string-name><given-names>A.B.</given-names> <surname>Younes</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Harper</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Pierron</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Lavandero</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Zitvogel</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Israel</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Baud</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Kroemer</surname></string-name>, <article-title>The IKK complex contributes to the induction of autophagy</article-title>, <source>The EMBO journal</source>, <volume>29</volume> (<year>2010</year>) <fpage>619</fpage>&#x2013;<lpage>631</lpage>.</mixed-citation></ref>
<ref id="c36"><label>[36]</label><mixed-citation publication-type="journal"><string-name><given-names>M.</given-names> <surname>Komatsu</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Kurokawa</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Waguri</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Taguchi</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Kobayashi</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Ichimura</surname></string-name>, <string-name><given-names>Y.S.</given-names> <surname>Sou</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Ueno</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Sakamoto</surname></string-name>, <string-name><given-names>K.I.</given-names> <surname>Tong</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Kim</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Nishito</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Iemura</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Natsume</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Ueno</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Kominami</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Motohashi</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Tanaka</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Yamamoto</surname></string-name>, <article-title>The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1</article-title>, <source>Nat Cell Biol</source>, <volume>12</volume> (<year>2010</year>) <fpage>213</fpage>&#x2013;<lpage>223</lpage>.</mixed-citation></ref>
<ref id="c37"><label>[37]</label><mixed-citation publication-type="journal"><string-name><given-names>M.</given-names> <surname>Komatsu</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Waguri</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Koike</surname></string-name>, <string-name><given-names>Y.S.</given-names> <surname>Sou</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Ueno</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Hara</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Mizushima</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Iwata</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Ezaki</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Murata</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Hamazaki</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Nishito</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Iemura</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Natsume</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Yanagawa</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Uwayama</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Warabi</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Yoshida</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Ishii</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Kobayashi</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Yamamoto</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Yue</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Uchiyama</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Kominami</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Tanaka</surname></string-name>, <article-title>Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice</article-title>, <source>Cell</source>, <volume>131</volume> (<year>2007</year>) <fpage>1149</fpage>&#x2013;<lpage>1163</lpage>.</mixed-citation></ref>
</ref-list>
</back>
</article>